4 results on '"Lucía Anza"'
Search Results
2. Cytotoxicity assay as potential alternative method to animal testing for batch release of Italian fish autogenous vaccines
- Author
-
Antonella Di-Paolo, Lucia Anzalone, Martina Pellegrini, Giulio Sveri, and Monica Cagiola
- Subjects
autogenous vaccine ,3rs ,in vitro testing ,aquaculture ,mts ,Zoology ,QL1-991 - Abstract
Background: Vaccination is widely used in fish aquaculture for three primary reasons: to prevent bacterial disease spreading, minimize antibiotic use and fight antibiotic resistance. Vaccine production is an expensive and consuming process, mainly in terms of money, resources and animals for quality control. The 3Rs (Replace-Reduce-Refine) philosophy suggests developing and validate alternative methods to animal testing for scientific purpose, even for biologicals and vaccines. Aim: The current study explored the potential use of mouse and fish cells in the in vitro toxicity grade assessment thorough different methods, as alternative assay to in vivo Residual Toxicity Test for autogenous fish vaccines control. Methods: BF2 and L929 cell lines were exposed to vaccines dilutions in two different ways of administration and toxicity grade was recorded by MTS assay, in comparison to the in vivo gold standard test. Results: AVs caused no reactions in the in vivo test. In the in vitro assay, the different toxicity grade recorded was statistically significant between the cell lines adopted and the AVs way of administration. Conclusion: Data obtained represent the first application of 3Rs method to fish autogenous vaccines produced in Italy, more investigations are needed to collect solid results and standardize new in vitro methods for vaccines quality control. [Open Vet J 2023; 13(4.000): 495-500]
- Published
- 2023
- Full Text
- View/download PDF
3. Expression of a recombinant ASFV P30 protein and production of monoclonal antibodies
- Author
-
Rosrio Liberti, Claudia Colabella, Lucia Anzalone, Giulio Severi, Antonella Di Paolo, Cristina Casciari, Anna Beatrice Casano, Monica Giammarioli, Monica Cagiola, Francesco Feliziani, and Antonio De Giuseppe
- Subjects
asfv ,asfv p30 protein ,baculovirus ,monoclonal antibody ,Zoology ,QL1-991 - Abstract
Background: African Swine Fever (ASF) is an infectious disease that affects domestic pig and wild boar populations. The African Swine Fever Virus (ASFV) has a genome characterized by a very complex DNA (170-193 kb) that encodes for more than 200 different proteins. Among these, the highly immunogenic phosphoprotein p30 plays a fundamental role in the induction of specific antibodies. To date, the lack of a vaccine against the disease requires continuous studies to improve knowledge about the virus and the development of new tests in addition to virological ones. Aim: The aim of this work was to produce specific monoclonal antibodies (mAbs) against the p30 protein of ASFV, which could find useful applications in routine diagnostics and the implementation of new diagnostic tools. Methods: ASFV p30 encoding gene was amplified and used for the generation of the recombinant baculovirus by transfection of the Sf21 insect cells. The recombinant protein was analyzed by immunofluorescence assay, purified, and used for mice Balb-c immunization. The hybridomas obtained were cultured and screened, using an indirect Enzyme-linked Immunosorbent Assay (iELISA), in order to select clones that secrete the mAbs of interest. Results: The expression of recombinant p30 protein was assessed using direct Immunofluorescence. The purified p30 protein fractions were analyzed by Coomassie gels staining confirming the presence of bands with a molecular weight of 30 kDa and used for the immunization of Balb-c mice. Six clones of pure hybridomas secreting the specific mAbs against recombinant p30 were obtained and tested in iELISA. The mAbs were also characterized by Western blot and Immunofluorescence assay. The best results were obtained with the anti-p30 mAb 2B8E10 clone which showed high reactivity with both recombinant and viral p30 protein, respectively. Conclusion: In this work, a recombinant p30 protein produced in an insect cell system was purified and used to immunize Balb-c mice. Six anti-p30 mAbs-secreting hybridomas clone cells were obtained. These mAbs displayed high reactivity against the recombinant protein, but only 2B8E10 mAb showed excellent functionality against the p30 protein produced by ASFV. These results open the possibility to develop different diagnostic assays. [Open Vet J 2023; 13(3.000): 358-364]
- Published
- 2023
- Full Text
- View/download PDF
4. Generation of recombinant baculovirus expressing atoxic C-terminal CPA toxin of Clostridium perfringens and production of specific antibodies
- Author
-
Katia Forti, Monica Cagiola, Martina Pellegrini, Lucia Anzalone, Antonella Di Paolo, Sara Corneli, Giulio Severi, and Antonio De Giuseppe
- Subjects
Clostridium perfringens ,L21 leader sequence ,Atoxic rBacCPA250–363H6 ,Affinity chromatography ,Recombinant vaccines ,Biotechnology ,TP248.13-248.65 - Abstract
Abstract Background Clostridium perfringens is the causative agent of several diseases and enteric infections in animals and humans. The virulence of C. perfringens is largely attributable to the production of numerous toxins; of these, the alpha toxin (CPA) plays a crucial role in histotoxic infections (gas gangrene). CPA toxin consists of two domains, i.e., the phospholipase C active site, which lies in the N-terminal domain amino acid (aa residues 1–250), and the C-terminal region (aa residues 251–370), which is responsible for the interaction of the toxin with membrane phospholipids in the presence of calcium ions. All currently produced clostridial vaccines contain toxoids derived from culture supernatants that are inactivated, mostly using formalin. The CPA is an immunogenic antigen; recently, it has been shown that mice that were immunized with the C-terminal domain of the toxin produced in E. coli were protected against C. perfringens infections and the anti-sera produced were able to inhibit the CPA activity. Monoclonal and polyclonal antibodies were produced only against full-length CPA and not against the truncated forms. Results In the present study, we have reported for the first time; about the generation of a recombinant baculovirus capable of producing a deleted rCPA toxin (rBacCPA250–363H6) lacking the N-terminal domain and the 28 amino acids (aa) of the putative signal sequence. The insertion of the L21 consensus sequence upstream of the translational start codon ATG, drastically increases the yield of recombinant protein in the baculovirus-based expression system. The protein was purified by Ni-NTA affinity chromatography and the lack of toxicity in vitro was confirmed in CaCo-2 cells. Polyclonal antibodies and eight hybridoma-secreting Monoclonal antibodies were generated and tested to assess specificity and reactivity. The anti-sera obtained against the fragment rBacCPA250–363H6 neutralized the phospholipase C activity of full-length PLC. Conclusions The L21 leader sequence enhanced the expression of atoxic C-terminal recombinant CPA protein produced in insect cells. The monoclonal and polyclonal antibodies obtained were specific and highly reactive. The availability of these biologicals could contribute to the development of diagnostic assays and/or new recombinant protein vaccines.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.